{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:43:07Z","timestamp":1769694187421,"version":"3.49.0"},"reference-count":77,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Roche Products Ltd."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,2,28]]},"DOI":"10.2217\/fon-2018-0480","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T15:03:37Z","timestamp":1540998217000},"page":"543-561","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Real-world use of Bevacizumab in Metastatic Colorectal, Metastatic Breast, Advanced Ovarian and Cervical Cancer: A Systematic Literature Review"],"prefix":"10.1080","volume":"15","author":[{"given":"Sherif","family":"Raouf","sequence":"first","affiliation":[{"name":"Department of Oncology \u2013 Clinical, Queen\u2019s Hospital, Rom Valley Way, Romford, RM7 0AG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfilippo","family":"Bertelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Singleton Hospital, Sketty Lane, Swansea, SA2 8QA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Ograbek","sequence":"additional","affiliation":[{"name":"Global Product Development \u2013 Medical Affairs Oncology, Roche Products Limited, Hexagon Place, Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polly","family":"Field","sequence":"additional","affiliation":[{"name":"Value Demonstration Practice, PharmaGenesis Oxford Central, 38\u00a0St Aldates, Chamberlain House, Oxford, OX1 1BN, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irwin","family":"Tran","sequence":"additional","affiliation":[{"name":"Global Access Department, Genentech Inc., 1 DNA Way, South San Francisco, CA94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0213"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6305"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt231"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1255"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6630"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2008.n.045"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.018"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0982"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.004"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70004-5"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.11.006"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4240"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309748"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.725"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.12.4781"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.958532"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.3_suppl.434"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9650"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.4_suppl.744"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2158-8"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9791-y"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0209"},{"issue":"131","key":"e_1_3_5_30_1","first-page":"633","article-title":"Addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer","volume":"61","author":"Tsutsumi S","year":"2014","unstructured":"Tsutsumi S , FujiiT, YamaguchiSet al. Addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer. Hepatogastroenterology61(131), 633\u2013637 (2014).","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"e_1_3_5_31_1","first-page":"PD-030","article-title":"Prospective non-interventional study to collect data on the use of bevacizumab and conventional chemotherapy for the treatment of previously untreated metastatic colorectal cancer in patient\u2019s \u226570 years","volume":"27","author":"Van Cutsem E","year":"2016","unstructured":"Van Cutsem E , DecosterL, HoubiersGet al. Prospective non-interventional study to collect data on the use of bevacizumab and conventional chemotherapy for the treatment of previously untreated metastatic colorectal cancer in patient\u2019s \u226570 years. Ann. Oncol.27(Suppl. 2), PD-030 (2016).","journal-title":"Ann. Oncol."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.24425"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.188946"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(20)30181-2"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.02.007"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt253"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2016.17.2.539"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12639"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.04.009"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004531"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12469"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1741-0"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv233.265"},{"key":"e_1_3_5_44_1","volume-title":"2016 Gastrointestinal Cancer Symposium","author":"Houts AC","year":"2016","unstructured":"Houts AC , OgaleS, SommerN, WalkerMS. Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens. Presented at: 2016 Gastrointestinal Cancer Symposium. San Francisco, CA, USA, 21\u201323 January 2016 (Abstract 159503)."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv340.15"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1829-6"},{"key":"e_1_3_5_47_1","first-page":"S185","article-title":"Implementation and effectiveness of bevacizumab in metastatic breast cancer: a real world study","volume":"50","author":"De Boer M","year":"2014","unstructured":"De Boer M , Van KampenRJW, LobbezooDJAet al. Implementation and effectiveness of bevacizumab in metastatic breast cancer: a real world study. Eur. J. Cancer50, S185 (2014).","journal-title":"Eur. J. Cancer"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.e11525"},{"issue":"1","key":"e_1_3_5_49_1","first-page":"227","article-title":"Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis","volume":"34","author":"Gampenrieder SP","year":"2014","unstructured":"Gampenrieder SP , RomederF, MusCet al. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer Res.34(1), 227\u2013233 (2014).","journal-title":"Anticancer Res."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(16)30823-1"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e12035"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25685"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw260"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.12.263"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.01.009"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31829f17c9"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.05.031"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.04.139"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00086-8"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"issue":"3","key":"e_1_3_5_62_1","first-page":"274","article-title":"Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab","volume":"6","author":"Al-Shamsi HO","year":"2015","unstructured":"Al-Shamsi HO , Al FarsiA, AnjumMet al. Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. J. Gastrointest. Oncol.6(3), 274\u2013279 (2015).","journal-title":"J. Gastrointest. Oncol."},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-012-9303-z"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.08.1110"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12094"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168707"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.3544"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.e14623"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12138"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.7368"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181deb67f"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S97874"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer.15.47"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0190"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1159\/000320222"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp233"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:56Z","timestamp":1719125156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,2,28]]}},"alternative-id":["10.2217\/fon-2018-0480"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0480","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}